Research programme: melanocortin-4 receptor antagonists - Gene Logic

Drug Profile

Research programme: melanocortin-4 receptor antagonists - Gene Logic

Alternative Names: Melanocortin-4 receptor antagonists research programme - Gene Logic

Latest Information Update: 27 Jul 2004

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Gene Logic
  • Class
  • Mechanism of Action Melanocortin type 4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cachexia

Most Recent Events

  • 27 Jul 2004 Gene Logic has acquired the MC4 antagonist research programme from Millennium Pharmaceuticals
  • 04 Jun 2004 Discontinued - Preclinical for Cachexia in USA (unspecified route)
  • 23 Jul 1999 Preclinical development for Cachexia in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top